(ChemotherapyAdvisor) – A urine-based assay “can markedly improve the accuracy” of detecting bladder cancer noninvasively, according to a case-controlled validation study reported during the 2013 Genitourinary Cancers Symposium in Orlando, FL.
Based on the study results, “further validation studies are underway to investigate the clinical utility of this panel of biomarkers for bladder cancer diagnosis and disease monitoring,” stated Charles J. Rosser, MD, MBA, a urologic oncology physician for the Genitourinary Cancer Department at M.D. Anderson Cancer Center, Orlando, and colleagues.
“Accurate urinary assays for bladder cancer detection would benefit both patients and healthcare systems,” he noted. “Through genomic and proteomic profiling of urine components, we have previously identified a panel of biomarkers that can outperform current urine-based biomarkers for the noninvasive detection of bladder cancer.”
Continue Reading
To report the diagnostic utility of multivariate biomarker combinations, the investigators analyzed voided urine samples from 550 patients, 220 of whom were known to have tumors. They used enzyme-linked immunosorbent assay to assess the urinary concentrations of 14 biomarkers, IL-8, MMP-9,MMP-10, SDC1, CCL18, PAI-1, CD44, VEGF, ANG, CA9, A1AT, OPN, PTX3, and APOE.
When the diagnostic performance of each biomarker and multivariate models were compared using receiver operating characteristic curves and the chi-square test, “a 3-biomarker model (CA9, PAI-1, and IL-8) achieved the most accurate bladder cancer diagnosis (sensitivity 90%, specificity 88%),” Dr. Rosser noted.
The 2013 Genitourinary Cancers Symposium is co-sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO).
